CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Cycle Pharmaceuticals, Inc. (Cycle) announces today completion of the acquisition of Banner Life Sciences, LLC (Banner) which includes its BAFIERTAM® (monomethyl fumarate) product for the treatment of relapsing forms of multiple sclerosis (MS), in adults, approved by the US Food and Drug Administration (FDA). MS affects an estimated 1 million people in the US with around 200 new cases being diagnosed each week.1 Approximately 85% of diagnoses are th
Go to Source
Author: